ArticleExperimental and therapeutic medicine2017

Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Yitao Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.